Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03502824 · ClinicalTrials.gov registry record · NA
PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.
A NA study, sponsored by Organogenesis.
- Terminated
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT03502824 is a NA study that was terminated before completion, run by Organogenesis. The registered enrollment target is 40 participants.
The verdict
NCT03502824, a NA study, was terminated before completion, sponsored by Organogenesis.
- TERMINATED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a prospective, multi-center, randomized, controlled clinical study Of PuraPly® AM and standard of care (SOC) compared to SOC alone for the management of Stage II-IV pressure ulcers located in the gluteal, ischial, hip, sacral, coccygeal, and trochanteric, malleolus, or heel area.
Interventions
- DEVICE PuraPly® Antimicrobial Wound Matrix
- OTHER SOC for Pressure Ulcers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2021-09-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03502824
The ClinicalTrials.gov registry entry for NCT03502824 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Organogenesis, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PuraPly® Antimicrobial Wound Matrix is the first listed.
NCT03502824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03502824 about?
NCT03502824 is a clinical study titled "PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.". This is a prospective, multi-center, randomized, controlled clinical study Of PuraPly® AM and standard of care (SOC) compared to SOC alone for the management of Stage II-IV pressure ulcers located in the gluteal, ischial, hip, sacral, coccygeal, and trochanteric, malleolus, or heel area.
What is the current status of trial NCT03502824?
This trial is currently terminated. It is a NA study. The enrollment target is 40 participants. The study started on 2018-05-01. Estimated completion is 2021-09-15.
What interventions are being tested in trial NCT03502824?
The interventions under investigation include: PuraPly® Antimicrobial Wound Matrix (DEVICE), SOC for Pressure Ulcers (OTHER).
Who is sponsoring clinical trial NCT03502824?
This trial is sponsored by Organogenesis, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.